PDCD1 and melanoma: The advent of immune checkpoint inhibitor (ICI), including programmed cell death protein 1 (PD-1) and its ligand 1 (PD-L1), has brought a paradigm shift in melanoma therapy [18], but more than half of patients fail to exhibit clinical responses [19].